Work

NCI9782: A phase 1 study of talazoparib in combination with carboplatin and paclitaxel in patients with advanced solid tumors.

Year: 2018

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2018.36.15_suppl.2548

Authors: Anita Ahmed Turk, Ticiana A.B. Leal, Nancy Chan, Robert Wesolowski, Ruth O'Regan, Mark E. Burkard, Amye Tevaarwerk, Laurel Rice, Toby Christopher Campbell, Justine Yang Bruce, Jyoti Malhotra, Lisa Marie Barroilhet, Janice M. Mehnert, Jens C. Eickhoff, Glenn Liu, Kari Braun Wisinski

Institutions: University of Wisconsin–Madison, University of Wisconsin Carbone Cancer Center, Rutgers Cancer Institute, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University

Language: English

Topic: PARP inhibition in cancer therapy

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4242588491

Cites:

Cited by:

Related to: 10